Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

Alessandro M. Vannucchi, Annalisa Pacilli, PhD, Giada Rotunno, MSc, PhD, Francesco Mannelli, Chiara Paoli, BiSci, Carmela Mannarelli, MSc, PhD, Annalisa Franci, RN, Tiziana Fanelli, BiSc, Alessandro Pancrazzi, PhD, Francesca Gesullo, MSc, Giuditta Corbizi Fattori, BiSc, Alberto Bosi, MD, Paola Guglielmelli, MD PhD

Blood (2017) 130 (Supplement 1): 4195.

https://doi.org/10.1182/blood.V130.Suppl_1.4195.4195

Published: 2017

Journal Articles

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

Alessandro M. Vannucchi, Paola Guglielmelli, MD PhD, Terra L. Lasho, PhD, Giada Rotunno, MSc, PhD, Carmela Mannarelli, MSc, PhD, Annalisa Pacilli, PhD, Animesh Pardanani, MBBS PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Curtis A. Hanson, MD, Francesco Mannelli, Rhett P. Ketterling, MD, Naseema Gangat, MBBS, Alessandro Rambaldi, MD Prof, Francesco Passamonti, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Ayalew Tefferi, MD

Blood (2017) 130 (Supplement 1): 200.

https://doi.org/10.1182/blood.V130.Suppl_1.200.200

Published: 2017

Journal Articles

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Blood (2017) 130 (Supplement 1): 1657.

https://doi.org/10.1182/blood.V130.Suppl_1.1657.1657

Published: 2017

Journal Articles

Prognotic Impact of Mutations in Systemic Mastocytosis

Lisa Pieri, MD PhD, Giada Rotunno, MSc, PhD, Francesca Gesullo, MSc, Tiziana Fanelli, MSc, Giuditta Corbizi Fattori, MSc, Annalisa Pacilli, PhD, Federica Scarfì, MD, Maria Loredana Iorno, MD, Fabio Almerigogna, MD, Roberto Salerno, MD, Paola Guglielmelli, MD PhD, Roberta Zanotti, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 1953.

https://doi.org/10.1182/blood.V128.22.1953.1953

Published: 2016

Journal Articles

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Paola Guglielmelli, PhDMD, Giada Rotunno, MSc, PhD, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Daniela Pietra, PhD, Silvia Salmoiraghi, BSc, Carmela Mannarelli, MSc, PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 943.

https://doi.org/10.1182/blood.V128.22.943.943

Published: 2016

Journal Articles

Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Alessandro Pancrazzi, BS, Tiziana Fanelli, MSc, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Chiara Paoli, BS, Lucia Merli, BSN, Marker Mahtab, Ana Rodriguez, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4087.

https://doi.org/10.1182/blood.V126.23.4087.4087

Published: 2015

Journal Articles

Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes

Giada Rotunno, MSc, Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Tiziana Fanelli, MSc, Carmela Mannarelli, MSc, Alessandro Pancrazzi, BS, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4091.

https://doi.org/10.1182/blood.V126.23.4091.4091

Published: 2015

Journal Articles

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Francesca Gesullo, BS, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Carmela Mannarelli, MSc, Giuseppe Loscocco, Chiara Paoli, BS, Lucia Merli, BSN, Alessandro M. Vannucchi

Blood (2015) 126 (23): 353.

https://doi.org/10.1182/blood.V126.23.353.353

Published: 2015

Journal Articles

A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis

Paola Guglielmelli, MD PhD, Giada Rotunno, MSc, Tiziana Fanelli, MSc, Annalisa Pacilli, PhD, Laura Calabresi, BiSci, Alessandro Pancrazzi, BS, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1627.

https://doi.org/10.1182/blood.V126.23.1627.1627

Published: 2015

Journal Articles

Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis

Blood (2015) 126 (23): 2830.

https://doi.org/10.1182/blood.V126.23.2830.2830

Published: 2015

Journal Articles

Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis

Ayalew Tefferi, MD, Paola Guglielmelli, PhDMD, Terra L. Lasho, PhD, Yoseph Elala, MD, Tiziana Fanelli, MSc, Naseema Gangat, MBBS, Christy Finke, BS, Giada Rotunno, MSc, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Animesh Pardanani, MBBS, PhD, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 2801.

https://doi.org/10.1182/blood.V126.23.2801.2801

Published: 2015

Journal Articles

JAK2 V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib

Lisa Pieri, MDPhD, Alessandro Pancrazzi, MSc, Annalisa Pacilli, PhD, Claudia Rabuzzi, BSci, Giada Rotunno, MSc, Paola Guglielmelli, MD PhD, Rajmonda Fjerza, MD, Chiara Paoli, MSc, Tiziana Fanelli, MSc, Alberto Bosi, MD, Srdan Verstovsek, MD PhD, Alessandro Maria Vannucchi, MD

Blood (2014) 124 (21): 3185.

https://doi.org/10.1182/blood.V124.21.3185.3185

Published: 2014

Journal Articles

Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2 V617F Mutation: A Study from the AGIMM Group

Blood (2014) 124 (21): 3179.

https://doi.org/10.1182/blood.V124.21.3179.3179

Published: 2014

Journal Articles

Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study

Blood (2014) 124 (21): 1867.

https://doi.org/10.1182/blood.V124.21.1867.1867

Published: 2014

Journal Articles

Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project

Blood (2014) 124 (21): 405.

https://doi.org/10.1182/blood.V124.21.405.405

Published: 2014

NARROW

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Prognotic Impact of Mutations in Systemic Mastocytosis

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study

Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis

Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis

Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis

JAK2 V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib

Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2 V617F Mutation: A Study from the AGIMM Group

Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study

Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only